Quality of life of inflammatory bowel diseases patients in france with EQ-5D-5 L: the QALY-MICI study.
EQ-5D-5L
France
Inflammatory bowel disease
Utility values
Journal
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
ISSN: 1573-2649
Titre abrégé: Qual Life Res
Pays: Netherlands
ID NLM: 9210257
Informations de publication
Date de publication:
29 Oct 2024
29 Oct 2024
Historique:
accepted:
21
10
2024
medline:
29
10
2024
pubmed:
29
10
2024
entrez:
29
10
2024
Statut:
aheadofprint
Résumé
This study aimed to document utility values and the Visual Analog Scale (VAS) with the 5-level version of the EQ-5D questionnaire in a large sample of patients with inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC). QALY-MICI was a cross-sectional survey across three sources in France. Data were collected between 2019 and 2022 for patients 18 and over. The EQ-5D-5 L, the EQ-VAS, the Short Inflammatory Bowel Disease Questionnaire (SIBDQ), the Harvey-Bradshaw Index (HBI) for CD, and the Walmsley Index for UC (SCCAI) were collected. A total of 2,841 patients aged over 18 were recruited (1785 with CD, 1056 with UC). The mean age was 40.2 (SD 14.3). The time since diagnosis was 6 years and over for 61.9% of patients. The most impacted dimensions were usual activities, anxiety/ depression, and pain/ discomfort. The mean utility value was 0.863 (SD 0.172) versus 0.905 (SD 0.158) in the French population (p = 0.007). The mean VAS value was 68 (SD 19.2) versus 73.4 (SD 22.2) in the general population (p = 0.016). Utility values and VAS were similar for CD and UC and higher for men. There was a strong positive correlation between utility values, the VAS, and the SIBDQ score, and a negative correlation between the HBI and the SCCAI. The SIBDQ score and disease activity were the main predictors of utility and VAS. The QALY-MICI is, to our knowledge, the first study documenting utility values and VAS using the EQ-5D-5 L questionnaire on a large sample, with a comparison to the general population. Cost-effectiveness analyses have become an important component of assessing new health technologies. They require robust evidence to measure Quality of Life Adjusted Life Year gains. The Euroqol EQ-5D questionnaire is the main standard.Data on its use in inflammatory bowel disease (IBD) with its latest version, EQ-5D-5L, are limited to small samples.This study aimed at estimating utility values for IBD patients on a large sample in France, analysing the relationship between specific IBD quality of life and disease activity indexes, and identifying the main factors impacting patients’ quality of life.A prospective, cross-sectional survey was designed amongst French IBD patients aged 18 and over from three sources (n=2,841) . Utility values for IBD patients were lower than those observed in the French general population across all age groups. Men declared higher values than women. There was no difference between patients with Crohn’s disease and those with ulcerative colitis. Patients with a quiescent disease had similar values to those of the general population.
Autres résumés
Type: plain-language-summary
(eng)
Cost-effectiveness analyses have become an important component of assessing new health technologies. They require robust evidence to measure Quality of Life Adjusted Life Year gains. The Euroqol EQ-5D questionnaire is the main standard.Data on its use in inflammatory bowel disease (IBD) with its latest version, EQ-5D-5L, are limited to small samples.This study aimed at estimating utility values for IBD patients on a large sample in France, analysing the relationship between specific IBD quality of life and disease activity indexes, and identifying the main factors impacting patients’ quality of life.A prospective, cross-sectional survey was designed amongst French IBD patients aged 18 and over from three sources (n=2,841) . Utility values for IBD patients were lower than those observed in the French general population across all age groups. Men declared higher values than women. There was no difference between patients with Crohn’s disease and those with ulcerative colitis. Patients with a quiescent disease had similar values to those of the general population.
Identifiants
pubmed: 39470874
doi: 10.1007/s11136-024-03821-x
pii: 10.1007/s11136-024-03821-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Amgen France
ID : Amgen France
Organisme : Biogaran
ID : Biogaran
Organisme : Janssen Research and Development
ID : Janssen Research and Development
Organisme : Merck Sharp and Dohme France
ID : Merck Sharp and Dohme France
Organisme : EuroQol Research Foundation
ID : EuroQol Research Foundation
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Alrubaiy, L., Rikaby, I., Dodds, P., Hutchings, H. A., & Williams, J. G. (2015). Systematic review of health-related quality of life measures for inflammatory bowel disease. J Crohns Colitis, 9(3), 284–292. https://doi.org/10.1093/ecco-jcc/jjv002 Epub 2015 Jan 9.
pubmed: 25576752
Armuzzi, A., Tarallo, M., Lucas, J., Bluff, D., Hoskin, B., Bargo, D., Cappelleri, J. C., Salese, L., & daCosta DiBonaventura, M. (2020). The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe. Bmc Gastroenterology, 20(1), 18. https://doi.org/10.1186/s12876-020-1164-0
pubmed: 31964359
pmcid: 6975026
Benedini V., Caporaso N., Corazza GR., Rossi Z., Fornaciari G., Cottone M., Frosini G., Caruggi M., Ottolini C., Colombo G.L.Burden of Crohn’s disease: economics and quality of life aspects in Italy. Clinicoecon Outcomes Res. 2012;4:209-18. doi: 10.2147/CEOR.S31114.
Gibson, P. R., Vaizey, C., Black, C. M., Nicholls, R., Weston, A. R., Bampton, P., Sparrow, M., Lawrance, I. C., Selby, W. S., Andrews, J. M., Walsh, A. J., Hetzel, D. J., Macrae, F. A., Moore, G. T., Weltman, M. D., Leong, R. W., & Fan, T. (2014). Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: A cross-sectional, observational study. J Crohns Colitis, 8(7), 598–606. https://doi.org/10.1016/j.crohns.2013.11.017
pubmed: 24345767
Knowles, S. R., Graff, L. A., Wilding, H., Hewitt, C., Keefer, L., & Mikocka-Walus, A. (2018). Quality of life in inflammatory bowel disease: A systematic review and Meta-analyses-part I. Inflammatory Bowel Diseases, 24(4), 742–751. https://doi.org/10.1093/ibd/izx100
pubmed: 29562277
Knowles, S. R., Keefer, L., Wilding, H., Hewitt, C., Graff, L. A., & Mikocka-Walus, A. (2018). Quality of life in inflammatory bowel disease: A systematic review and Meta-analyses-part II. Inflammatory Bowel Diseases, 24(5), 966–976. https://doi.org/10.1093/ibd/izy015
pubmed: 29688466
Van Assche, G., Peyrin-Biroulet, L., Sturm, A., Gisbert, J. P., Gaya, D. R., Bokemeyer, B., Mantzaris, G. J., Armuzzi, A., Sebastian, S., Lara, N., Lynam, M., Rojas-Farreras, S., Fan, T., Ding, Q., Black, C. M., & Kachroo, S. (2016). Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months - multicenter European cohort study. Digestive and Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 48(6), 592–600. https://doi.org/10.1016/j.dld.2016.01.011
pubmed: 26935454
van der Have, M., van der Aalst, K. S., Kaptein, A. A., Leenders, M., Siersema, P. D., Oldenburg, B., & Fidder, H. H. (2014). Determinants of health-related quality of life in Crohn’s disease: A systematic review and meta-analysis. J Crohns Colitis, 8(2), 93–106. https://doi.org/10.1016/j.crohns.2013.04.007
pubmed: 23746864
Vaizey, C. J., Gibson, P. R., Black, C. M., Nicholls, R. J., Weston, A. R., Gaya, D. R., Sebastian, S., Shaw, I., Lewis, S., Bloom, S., Gordon, J. N., Beale, A., Arnott, I., Campbell, S., & Fan, T. (2014). Disease status, patient quality of life and healthcare resource use for ulcerative colitis in the UK: An observational study. Frontline Gastroenterol, 5(3), 183–189. https://doi.org/10.1136/flgastro-2013-100409 Epub 2014 Jan 24.
pubmed: 28839768
pmcid: 5369729
Williet, N., Sarter, H., Gower-Rousseau, C., Adrianjafy, C., Olympie, A., Buisson, A., Beaugerie, L., & Peyrin-Biroulet, L. (2017). Patient-reported outcomes in a French Nationwide Survey of Inflammatory Bowel Disease patients. J Crohns Colitis, 11(2), 165–174. https://doi.org/10.1093/ecco-jcc/jjw145 Epub 2016 Aug 11.
pubmed: 27516406
Casellas, F., López Vivancos, J., & MalagelaJR (2003). Previous experience and quality of life in patients with inflammatory bowel disease during relapse. Revista Espanola De Enfermedades Digestivas, 95(7), 476–479. English, Spanish.
König, H. H., Ulshöfer, A., Gregor, M., von Tirpitz, C., Reinshagen, M., Adler, G., & Leidl, R. (2002). Validation of the EuroQol questionnaire in patients with inflammatory bowel disease. European Journal of Gastroenterology and Hepatology, 14(11), 1205–1215. https://doi.org/10.1097/00042737-200211000-00008
pubmed: 12439115
Casellas, F., Arenas, J. I., Baudet, J. S., Fábregas, S., García, N., Gelabert, J., Medina, C., Ochotorena, I., Papo, M., Rodrigo, L., & Malagelada, J. R. (2005). Impairment of health-related quality of life in patients with inflammatory bowel disease: A Spanish multicenter study. Inflammatory Bowel Diseases, 11(5), 488–496. https://doi.org/10.1097/01.mib.0000159661.55028.56
pubmed: 15867589
Min Ho, P. Y., Hu, W., Lee, Y. Y., Gao, C., Tan, Y. Z., Cheen, H. H., Wee, H. L., Lim, T. G., & Ong, W. C. (2019). Health-related quality of life of patients with inflammatory bowel disease in Singapore. Intest Res, 17(1), 107–118. https://doi.org/10.5217/ir.2018.00099 Epub 2018 Nov 12. PMID: 30419638.
pubmed: 30419638
Huppertz-Hauss, G., Aas, E., Lie Høivik, M., Langholz, E., Odes, S., Småstuen, M., Stockbrugger, R., Hoff, G., Moum, B., & Bernklev, T. (2016). Comparison of the Multiattribute Utility instruments EQ-5D and SF-6D in a Europe-wide Population-based cohort of patients with inflammatory bowel Disease 10 years after diagnosis. Gastroenterology Research and Practice, 2016, 5023973. https://doi.org/10.1155/2016/5023973 Epub 2016 Aug 18.
pubmed: 27630711
pmcid: 5007312
Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., Bonsel, G., & Badia, X. (2011). Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life Research, 20(10), 1727–1736. https://doi.org/10.1007/s11136-011-9903-x
pubmed: 21479777
pmcid: 3220807
Ghosh, C. K., Islam, S., Tabassum, N., Mohiuddin, S. A., Hossain, M. M., Sarkar, A., & Bari, A. (2023). Quality of life of patients with inflammatory bowel disease in Bangladesh. Cureus, 15(6), e39929. https://doi.org/10.7759/cureus.39929
pubmed: 37283595
pmcid: 10239544
Parra, R. S., Chebli, J. M. F., Amarante, H. M. B. S., Flores, C., Parente, J. M. L., Ramos, O., Fernandes, M., Rocha, J. J. R., Feitosa, M. R., Feres, O., Scotton, A. S., Nones, R. B., Lima, M. M., Zaltman, C., Goncalves, C. D., Guimaraes, I. M., Santana, G. O., Sassaki, L. Y., Hossne, R. S., Bafutto, M., Junior, R. L. K., Faria, M. A. G., Miszputen, S. J., Gomes, T. N. F., Catapani, W. R., Faria, A. A., Souza, S. C. S., Caratin, R. F., Senra, J. T., & Ferrari, M. L. A. (2019). Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil. World Journal of Gastroenterology, 25(38), 5862–5882. https://doi.org/10.3748/wjg.v25.i38.5862
pubmed: 31636478
pmcid: 6801193
Gao, Z., Wang, P., Hong, J., Yan, Y., Tong, T., Wu, B., Hu, J., & Wang, Z. (2022). Health-related quality of life among Chinese patients with Crohn’s disease: A cross-sectional survey using the EQ-5D-5L. Health and Quality of Life Outcomes, 20(1), 62. https://doi.org/10.1186/s12955-022-01969-z
pubmed: 35413910
pmcid: 9003980
Hagelund, L. M., Elkjær Stallknecht, S., & Jensen, H. H. (2020). Quality of life and patient preferences among Danish patients with ulcerative colitis - results from a survey study. Current Medical Research and Opinion, 36(5), 771–779. Epub 2020 Jan 24.
pubmed: 31944145
Steiner, I. M., Bokemeyer, B., & Stargardt, T. Mapping from SIBDQ to EQ-5D-5L for patients with inflammatory bowel disease. Eur J Health Econ 2023 Jun 27. https://doi.org/10.1007/s10198-023-01603-9
Irvine, E. J., Zhou, Q., & Thompson, A. K. (1996). The short inflammatory bowel Disease Questionnaire: A quality of life instrument for community physiciyears managing inflammatory bowel disease. CCRPT investigators. Canadian Crohn’s Relapse Prevention Trial. The American Journal of Gastroenterology, 91, 1571–1578.
pubmed: 8759664
Rencz, F., Lakatos, P. L., Gulácsi, L., Brodszky, V., Kürti, Z., Lovas, S., Banai, J., Herszényi, L., Cserni, T., Molnár, T., Péntek, M., & Palatka, K. (2019). Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn’s disease. Quality of Life Research, 28(1), 141–152. https://doi.org/10.1007/s11136-018-2003-4 Epub 2018 Sep 17.
pubmed: 30225788
Panés, J., Domènech, E., Aguas Peris, M., Nos, P., Riestra, S., Juliá de Páramo, B., Cea-Calvo, L., Romero, C., & Marín-Jiménez, I. (2017). Association between disease activity and quality of life in ulcerative colitis: Results from the CRONICA-UC study. Journal of Gastroenterology and Hepatology, 32(11), 1818–1824. https://doi.org/10.1111/jgh.13795
pubmed: 28370253
Gower-Rousseau, C., Salomez, J. L., Dupas, J. L., et al. (1994). Incidence of inflammatory bowel disease in northern France (1988–1990). Gut, 35, 1433–1438. https://doi.org/10.1136/gut.35.10.1433
pubmed: 7959201
pmcid: 1375020
Wolf, T., Lewis, A., Beaugerie, L., et al. (2023). Risk of colorectal neoplasia according to histologic disease activity in patients with inflammatory bowel disease and colonic post-inflammatory polyps. Alimentary Pharmacology & Therapeutics, 57, 1445–1452. https://doi.org/10.1111/apt.17495
Harvey, R. F., & Bradshaw, J. M. (1980). A simple index of Crohn’s-disease activity. Lancet, 1(8167), 514. https://doi.org/10.1016/s0140-6736(80)92767-1
pubmed: 6102236
Walmsley, R. S., Ayres, R. C., Pounder, R. E., & Allan, R. N. (1998). A simple clinical colitis activity index. Gut, 43(1), 29–32. https://doi.org/10.1136/gut.43.1.29
pubmed: 9771402
pmcid: 1727189
Turner, D., Ricciuto, A., Lewis, A., D’Amico, F., Dhaliwal, J., Griffiths, A. M., Bettenworth, D., Sandborn, W. J., Sands, B. E., Reinisch, W., Schölmerich, J., Bemelman, W., Danese, S., Mary, J. Y., Rubin, D., Colombel, J. F., Peyrin-Biroulet, L., Dotan, I., Abreu, M. T., Dignass, A., & International Organization for the Study of IBD. (2021). STRIDE-II: An update on the selecting therapeutic targets in inflammatory bowel Disease (STRIDE) Initiative of the International Organization for the study of IBD (IOIBD): Determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology, 160(5), 1570–1583. https://doi.org/10.1053/j.gastro.2020.12.031
pubmed: 33359090
Assurance Maladie (Personnes prises en charge pour maladies inflammatoires chroniques intestinales en 2021). https://www.google.com/url?sa=t/rct=j/q=/esrc=s/source=web/cd=/cad=rja/uact=8/ved=2ahUKEwi0l5Ss4ueEAxVQUqQEHdMvAREQFnoECBsQAQ/url=https%3A%2F%2Fassurance-maladie.ameli.fr%2Fetudes-et-donnees%2Fcartographie-fiche-mici/usg=AOvVaw2-w_Lc8NvDi_dBe3A99JB-/opi=89978449
Gautier, L., Azzi, J., Saba, G., Bonnelye, G., & de Pouvourville, G. (2023). Population norms in France with EQ-5D-5L: Health states, value indexes, and VAS. The European Journal of Health Economics, 24(9), 1517–1530. https://doi.org/10.1007/s10198-022-01559-2
pubmed: 36625971